The cancer cell secretome: A good source for discovering biomarkers?

• Published in: Journal of proteomics Vol. 73; no. 10; pp. 1896 - 1906
• Main Authors: Pavlou, Maria P., Diamandis, Eleftherios P.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 10.09.2010
• Subjects: Biomarkers, Tumor - analysis; Breast Neoplasms - diagnosis; Cancer biomarkers; Cell Line, Tumor; Colorectal Neoplasms - diagnosis; Early Diagnosis; Female; Humans; Lung Neoplasms - diagnosis; Male; Mass spectrometry; Neoplasms - diagnosis; Neoplasms - metabolism; Neoplasms - secretion; Pancreatic Neoplasms - diagnosis; Prostatic Neoplasms - diagnosis; Proteomic analysis; Proximal fluids; Secretome; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue culture; DIGE; IHC; Proximal fluids; Tissue culture; MALDI-MS; SCX; Proteomic analysis; CRMP-2; HNP; RP-LC-MS/MS; TCTP; RbAp46; LC-MS/MS; ALCAM; IGFBP-2; DMBT1; RT-PCR; CEA; PSA; NSE; AD; ROC; 1-D; PAGE; Secretome; LCC; CRC; CA-125; MMP-9; Mass spectrometry; ELISA; TPA; DDH; CA 15-3; A1BG; AFP; TPI; nano-HPLC-ESI-MS/MS; PCa; SRM; CA 19-9; SC; LDHB; MudPIT; i-TRAQ; SCLC; NSCLC; ProGRP; MALDI; 2-D; TMA; CM; DJ1; SILAC; SELDI-TOF/MS; ICAT; Cancer biomarkers; CT; NAF; PC; DRE; PGP9.5; FOBT; HIP/PAP-I; IPA; CYFRA 21-1
• ISSN: 1874-3919; 1876-7737
• DOI: 10.1016/j.jprot.2010.04.003

Cancer is a leading cause of death. Early detection is usually associated with better clinical outcomes. Recent advances in genomics and proteomics raised hopes that new biomarkers for diagnosis, prognosis or monitoring therapeutic response will soon be discovered. Proteins secreted by cancer cells, referred also as “the cancer cell secretome”, is a promising source for biomarker discovery. In this review we will summarize recent advances in cancer cell secretome analysis, focusing on the five most fatal cancers (lung, breast, prostate, colorectal, and pancreatic). For each cancer type we will describe the proteomic approaches utilized for the identification of novel biomarkers. Despite progress, identification of markers that are superior to those currently used has proven to be a difficult task and very few, if any, newly discovered biomarker has entered the clinic the last 10 years. (A) Phase contrast (I) and merge FRET-microscopy (II) images of cerebellar granule neurons stained with anti-L-VOCC/Alexa488-IgG and anti-C b 5R/Cy3-IgG. (B) Pixels analysis of neuronal somas: green (empty symbols) and red fluorescence (filled symbols). [Display omitted]